Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold

Alberto Briganti^{1

2}, Giorgio Gandaglia², Francesco Montorsi^{1

2}

Affiliations

¹ Vita-Salute San Raffaele University, Milan, Italy.
² Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Comment

Alberto Briganti et al. JAMA Oncol. 2020.

. 2020 Oct 1;6(10):1638-1639.

doi: 10.1001/jamaoncol.2020.2829.

Alberto Briganti^{1

2}, Giorgio Gandaglia², Francesco Montorsi^{1

2}

¹ Vita-Salute San Raffaele University, Milan, Italy.
² Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

No abstract available

Comment in

Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold-Reply.
Tran PT, Deek MP, Phillips RM. Tran PT, et al. JAMA Oncol. 2020 Oct 1;6(10):1639. doi: 10.1001/jamaoncol.2020.2842. JAMA Oncol. 2020. PMID: 32815993 No abstract available.

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Phillips R, et al. JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. JAMA Oncol. 2020. PMID: 32215577 Free PMC article. Clinical Trial.